Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with ad... Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.344827586207 | 2.9 | 2.985 | 2.8 | 859665 | 2.88576724 | CS |
4 | -0.13 | -4.30463576159 | 3.02 | 3.255 | 2.8 | 874959 | 2.96697994 | CS |
12 | -0.55 | -15.988372093 | 3.44 | 3.94 | 2.8 | 1028382 | 3.30175069 | CS |
26 | -1.44 | -33.2563510393 | 4.33 | 5.02 | 2.8 | 887940 | 3.74547789 | CS |
52 | -0.82 | -22.102425876 | 3.71 | 5.02 | 2.525 | 992345 | 3.6338203 | CS |
156 | 1.6 | 124.031007752 | 1.29 | 5.02 | 0.301 | 1443919 | 1.95188933 | CS |
260 | 1.15 | 66.091954023 | 1.74 | 5.02 | 0.301 | 1289475 | 2.3419777 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions